Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation

被引:253
作者
Thomas, DM
Walker, PD
Benjamins, JA
Geddes, TJ
Kuhn, DM
机构
[1] Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI 48201 USA
[2] Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA
[3] Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA
[4] Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48201 USA
[5] John D Dingell VA Med Ctr, Detroit, MI USA
关键词
D O I
10.1124/jpet.104.070961
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Methamphetamine intoxication causes long-lasting damage to dopamine nerve endings in the striatum. The mechanisms underlying this neurotoxicity are not known but oxidative stress has been implicated. Microglia are the major antigen-presenting cells in brain and when activated, they secrete an array of factors that cause neuronal damage. Surprisingly, very little work has been directed at the study of microglial activation as part of the methamphetamine neurotoxic cascade. We report here that methamphetamine activates microglia in a dose-related manner and along a time course that is coincident with dopamine nerve ending damage. Prevention of methamphetamine toxicity by maintaining treated mice at low ambient temperature prevents drug-induced microglial activation. MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), which damages dopamine nerve endings and cell bodies, causes extensive microglial activation in striatum as well as in the substantia nigra. In contrast, methamphetamine causes neither microglial activation in the substantia nigra nor dopamine cell body damage. Dopamine transporter antagonists ( cocaine, WIN 35,428 [(-)-2-beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane 1,5-naphthalenedisulfonate], and nomifensine), selective D1 (SKF 82958 [(+/-)-6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide]), D2 (quinpirole), or mixed D1/D2 receptor agonists ( apomorphine) do not mimic the effect of methamphetamine on microglia. Hyperthermia, a prominent and dangerous clinical response to methamphetamine intoxication, was also ruled out as the cause of microglial activation. Together, these data suggest that microglial activation represents an early step in methamphetamine-induced neurotoxicity. Other neurochemical effects resulting from methamphetamine-induced overflow of DA into the synapse, but which are not neurotoxic, do not play a role in this response.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 42 条
[1]   LOW ENVIRONMENTAL TEMPERATURES OR PHARMACOLOGICAL AGENTS THAT PRODUCE HYPOTHERMIA DECREASE METHAMPHETAMINE NEUROTOXICITY IN MICE [J].
ALI, SF ;
NEWPORT, GD ;
HOLSON, RR ;
SLIKKER, W ;
BOWYER, JF .
BRAIN RESEARCH, 1994, 658 (1-2) :33-38
[2]  
Ayoub AE, 2003, J NEUROSCI, V23, P7759
[3]   Methamphetamine increases dopamine transporter higher molecular weight complex formation via a dopamine- and hyperthermia-associated mechanism [J].
Baucum, AJ ;
Rau, KS ;
Riddle, EL ;
Hanson, GR ;
Fleckenstein, AE .
JOURNAL OF NEUROSCIENCE, 2004, 24 (13) :3436-3443
[4]  
BOWYER JF, 1994, J PHARMACOL EXP THER, V268, P1571
[5]   Phenobarbital and dizocilpine can block methamphetamine-induced neurotoxicity in mice by mechanisms that are independent of thermoregulation [J].
Bowyer, JF ;
Holson, RR ;
Miller, DB ;
O'Callaghan, JP .
BRAIN RESEARCH, 2001, 919 (01) :179-183
[6]   Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis [J].
Cadet, JL ;
Jayanthi, S ;
Deng, XL .
FASEB JOURNAL, 2003, 17 (13) :1775-1788
[7]   HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat [J].
Cass, WA ;
Harned, ME ;
Peters, LE ;
Nath, A ;
Maragos, WF .
BRAIN RESEARCH, 2003, 984 (1-2) :133-142
[8]   Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model [J].
Czlonkowska, A ;
Kohutnicka, M ;
Kurkowska-Jastrzebska, I ;
Czlonkowski, A .
NEURODEGENERATION, 1996, 5 (02) :137-143
[9]   Parkinson's disease: Mechanisms and models [J].
Dauer, W ;
Przedborski, S .
NEURON, 2003, 39 (06) :889-909
[10]  
DELLEDONNE KT, 1994, J PHARMACOL EXP THER, V271, P1320